Pregnancy

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating…

2 years ago

Albireo Announces 2022 SPARK Grant Winners

— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in…

2 years ago

Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001).In…

2 years ago

ICSI outcomes unchanged in men with normal or abnormal Cap-Scores™

ICSI fertilization rates and subsequent pregnancy rates were not different between men with normal or low Cap-ScoresMen with low Cap-Scores…

2 years ago

The Cap-Score™ is a more sensitive indicator of male fertility across age groups than traditional semen analysis

New study demonstrates the value of using the Cap-Score Test to assess the fertilizing ability in men of all ages…

2 years ago

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022

On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and…

2 years ago

SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in…

2 years ago

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

- Updated FemaSeed® LOCAL artificial insemination trial design focuses on male factor infertility in patient trial recruitment, with a goal…

2 years ago